Overview of Investor Relations Capabilities

ABOUT Rx COMMUNICATIONS

Specialists in the life science and healthcare industries

Partner-driven -- Senior level counsel on EVERY account

Partners have been through up and down market cycles, various political healthcare agendas and technology trends

ABOUT Rx COMMUNICATIONS

Experience with private and public companies – domestic and international

Focused on what we do best: Investor Relations and Financial Media Relations

Strong Wall Street and media contacts

Headquartered in New York City

PRIVATE COMPANIES

Services for Private Companies

WHY EMBARK ON AN IR/PR PROGRAM AS A PRIVATE COMPANY? Lay the groundwork for future

financings and eventual IPO

Assist with partnering activities by building corporate awareness

Build awareness of disease indications to generate product interest

Align company with reputable bankers

Become accustomed to working within disclosure rules i.e.; Reg FD

PROVIDING VALUE TO PRIVATE COMPANIES

Develop key messages positioned for analysts and investors

Develop collateral materials to tell story integrating key messages

Target and facilitate introductions to venture capitalists and institutional investors

Target and advise on corporate finance team

Target and facilitate introductions to sell-side analysts

PROVIDING VALUE TO PRIVATE COMPANIES

Build presence on the web

Develop story ideas for the media

Cultivate reporter interest

Introduce to conference circuit

Properly position company news

Develop company disclosure policy

ACTIVITIES SUROUNDING IPO

Assist in the selection of banking team – beginning of quiet period

Press release announcing registration for offering

Develop roadshow presentation Supplement banker’s list of target

institutions Presentation training

ACTIVITIES SURROUNDING IPO

“Teach-ins” at banks Roadshow Press release announcing completion

of IPO “Welcome letter” to new shareholders Create disclosure policy Quiet period lasts for 25 days

following the close of IPO

PUBLIC COMPANIES

Services for Public Companies

AFTER-MARKET SUPPORT

Need for continual dialogue with shareholders

On-going targeting of investors for future financings

Increase analyst coverage beyond banking support

Fulfill disclosure requirements Crisis communications Strategic media out-reach

GETTING STARTED: FIRST STEPS

Strategy session in order to immerse ourselves in corporate story

Define key message points Understand perceptions existent in

the marketplace Create targeted list of sell-side

analysts, venture capitalists and fund managers

GETTING STARTED: FIRST STEPS

Review collateral materials Create VIP blast e-mail/fax lists Develop media lists Design action plan

Rx COMMUNICATIONS CAPABILITIES

Strategic Counsel Roadshows Analyst Contact Investor Targeting Investment and Industry Conferences Follow-up and Analysis to Key Events Press Release Writing News Conferences/Press Briefings Video/Radio News Releases Fact Sheets Annual Reports

Rx COMMUNICATIONS CAPABILITIES

Crisis Communications Mergers and Acquisitions Positioning Strategy Perception Audits Conference Calls Presentation Training Placement Strategy Financial, Trade and Local Media

Contacts Slide Presentations Web Site Development

THE Rx TEAM

Melody A. Carey, Co-President

Founded Rx in 2000

Head of Corporate Communications and Spokesperson, Schein Pharmaceutical, Inc.

Director of Investor Relations, The Multicare Companies, Inc.

Executive, Noonan/Russo Communications

Former healthcare/life sciences investment banker, Kidder, Peabody & Co.

THE Rx TEAM

Rhonda Chiger, Co-President

Founded Rx in 2000

Senior Managing Director, Global Consulting Practice, Thomson Financial

Managed Life Sciences departments for Noonan/Russo and Dewe Rogerson

Established London office for healthcare investor relations firm

Former Manager, Investor Relations, American Stock Exchange

The Rx Team

Eric Goldman, Vice President

25 years experience in public relations and as a media relations strategist specializing in biotechnology, healthcare, technology and consumer products

Senior Director and Vice President at GlobalFluency

Handled media relations at Spector & Associates and Brouillard Communications, a division of J. Walter Thompson

Earned 2 Silver Anvil awards for public relations excellence

THE Rx TEAM

Paula B. Schwartz, Senior Vice President

Former Partner, FRB/Weber Shandwick, oldest and largest Investor Relations firm in the U.S.

Former Vice President, ECOM Consultants, Inc., an investor relations firm

Former Vice President/Director of Investor Relations Programs, KCS&A Public Relations, a public relations and investor relations consultancy

Rx COMMUNICATIONS CURRENT CLIENT LIST

ADMA Biologics, Inc. (Private)

Alexandria Real Estate Equities, Inc. (NYSE: ARE)

Alexion Pharmaceuticals Inc. (Nasdaq: ALXN)

Bio-Path Holdings, Inc. (OTCQX: BPTH)

Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX)

Complix (Private)

Glycotex, Inc. (Private)

Rx COMMUNICATIONS CURRENT CLIENT LIST

Intact Medical Corporation (Private)

MAXIMUS, Inc. (NYSE: MMS)

MolMed S.p.A. (Milan: MLM)

Neovacs, SA (Alternext Paris: ALNEV)

Omthera Pharmaceuticals, Inc. (Private)

PDI, Inc. (Nasdaq: PDII)

TetraLogic Pharmaceuticals (Private)

Theratechnologies (TSX: TH)

OURx SUCCESSES

Helped to grow Alexion Pharmaceuticals’ institutional shareholder base from 30% in 1996 to approximately 95% today.

Launched not-for-profit Immune Tolerance Institute resulting in broad coverage in the U.S. including CBS Radio Network, San Francisco Business Times and Drug Discovery News

Garnered coverage for Catalyst Pharmaceutical Partners’ compound for cocaine addiction. Placements included cover stories in Newsweek, Scientific American Mind and NeuroInvestment

OURx SUCCESSES

Designed and implemented IR program for American CareSource Holdings which led the company to be ranked as the number one stock performer on The NASDAQ Capital Market for 2008.

An aggressive investor outreach campaign on behalf of Genaissance Pharmaceuticals allowed Genaissance to regain compliance with Nasdaq’s $1 listing rule requirement.

Guided Kos Pharmaceuticals through a failed marketing alliance which caused over two million shares to trade (four times the average daily trading volume) and the stock never dropped below 2%.

OURx SUCCESSES

Arranged feature coverage focused on Hodgkins and non-Hodgkins lymphoma for MethylGene with Genetic Engineering News, Pink Sheet, BioCentury and Pharmawire

Guided ABIOMED on issues management surrounding FDA panel meeting. Put FDA’s request for additional data into perspective with reporters and investors. CNBC interview key part of strategy.

Implemented aggressive IR program for PharmAthene, Inc. which enabled the company to obtain coverage from two new sell-side analysts, garner investments from four new institutional funds and increase trading volume by three-fold within nine months.

OURx SUCCESSES

Rx Communications Group was honored with the 2008 Stevie Award for Best Investor Relations

Program for work on behalf of specialty

pharmaceutical company, NexMed, Inc.

We are pleased to announce that RxCommunications has been selected by PR Week

as a finalist forBoutique PR Agency of the Year

Rx Communications was named Best Small PR Agency

by League of American Communications Professionals

OURx SUCCESSES

Rx Communications was honored with the 2002 SABREAwards Certificate of Excellence for Building a North

American Investor Base for client Syngenta AG.

We are also pleased to share that our work for ImpactRx has won an Honorable Mention

Award in LACP’s (League of AmericanCommunications Professionals) 2002 Publicity

Campaign Competition.

Rx Communications received an honorable MentionAward from PR News, as part of the PR News Platinum PR

Awards 2003. The award was issued in theFinancial/Investor Relations category, for the company's

work on behalf of Genaissance Pharmaceuticals, Inc.

WHY Rx COMMUNICATIONS?

Specialist industry knowledge and expertise

Personal attention from Rx partners

Decades of experience in strategic counsel and implementation of financial public relations programs

Unique niche in working with private companies

Well versed in IPOs, secondary offerings, PIPEs, venture rounds and mergers and acquisitions

“The Street” knows and trusts us

For Additional Information:Rx Communications Group, LLC

445 Park Avenue10th Floor

New York, NY 10022(917) 322-2568www.RxIR.com